Stock Fundamentals

Company Information

Company Name
Erasca Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US29479A1088
CIK: 0001761918
CUSIP: 29479A108
Currency: USD
Full Time Employees: 103
Phone: 858 465 6511
Fiscal Year End: December
IPO Date: Jul 16, 2021
Description:

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Address:

3115 Merryfield Row, San Diego, CA, United States, 92121

Directors & Officers

Name Title Year Born
Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO 1972
Dr. David M. Chacko M.D. CFO & Chief Business Officer 1984
Dr. Michael D. Varney Ph.D. Chairman of Research & Development, Scientific Advisory Board Member and Director 1958
Dr. Shannon R. Morris M.D., Ph.D. Chief Medical Officer 1970
Dr. Nik Chetwyn Ph.D. Chief Operating Officer NA
Ms. Alison Tjosvold Milhous Senior Vice President of Accounting 1979
Dr. Robert Shoemaker Ph.D. Chief Scientific Officer 1981
Mr. Ebun S. Garner Esq., J.D. Chief Legal Officer & Corporate Secretary 1972
Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer NA
Mr. Brian L. Baker CPA, M.S. Senior Vice President of Finance 1967

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 01, 2026 Ebun Garner N/A Sale 80.00K $16.40 $1.31M
Mar 04, 2026 Shannon Morris N/A Sale 20.00K $15.04 $300.80K
Jan 07, 2026 Ebun Garner N/A Sale 120.00K $5.59 $670.80K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Frazier Life Sciences Management, L.P. 24.68M Mar 31, 2026 7.93% $10.27 8.56%
T. Rowe Price Investment Management,Inc. 21.26M Mar 31, 2026 6.84% $0.24 1.73%
BlackRock Inc 20.15M Mar 31, 2026 6.48% $0.01 29.20%
VR Adviser, LLC 16.38M Mar 31, 2026 5.27% $9.89 -8.26%
RTW INVESTMENTS, LLC 16.16M Mar 31, 2026 5.20% $2.60 10,917.43%
Vanguard Group Inc 12.81M Dec 31, 2025 4.12% $0.00 0.00%
Vivo Capital, LLC 12.15M Mar 31, 2026 3.91% $16.34 31.04%
Vanguard Capital Management, LLC 11.25M Mar 31, 2026 3.62% $0.00 0.00%
Siren, L.L.C. 11.24M Mar 31, 2026 3.62% $5.04 28.40%
Logos Global Management LP 11.15M Mar 31, 2026 3.59% $9.01 -14.23%
Paradigm Biocapital Advisors LP 10.39M Mar 31, 2026 3.34% $3.44 -26.60%
State Street Corp 9.30M Mar 31, 2026 2.99% $0.01 50.62%
ARCH VENTURE CORP 7.09M Mar 31, 2026 2.28% $16.95 -35.86%
Geode Capital Management, LLC 6.00M Mar 31, 2026 1.93% $0.01 21.72%
Cormorant Asset Management, LLC 5.80M Mar 31, 2026 1.87% $4.71 0.00%
Affinity Asset Advisors, LLC 5.35M Mar 31, 2026 1.72% $4.47 37.18%
Balyasny Asset Management LLC 5.14M Mar 31, 2026 1.65% $0.11 5,145.06%
The Goldman Sachs Group Inc 4.88M Mar 31, 2026 1.57% $0.01 46.34%
HHG PLC 3.71M Mar 31, 2026 1.19% $0.03 0.00%
5AM Venture Management, LLC 3.49M Mar 31, 2026 1.12% $15.66 -35.51%

Shares Statistics

Shares Outstanding: 310.98M
Shares Float: 207.89M
% Insiders: 1,065.80%
% Institutions: 9,355.00%
Short % Float: 11.66%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 8.38M 2.69% ▲ 0.81% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 5.24M 1.69% ▼ 0.61% May 31, 2026
3 iShares Russell 2000 ETF 4.55M 1.46% ▲ 0.93% May 29, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 2.69M 0.87% ▲ 1.05% Apr 30, 2026
5 T. Rowe Price Small-Cap Stock 2.57M 0.83% ▲ 0.76% Apr 30, 2026
6 T. Rowe Price US Small-Cap Core Equity 2.55M 0.82% ▼ 15.79% Mar 31, 2026
7 Fidelity Small Cap Index 1.86M 0.60% ▲ 9.47% Mar 31, 2026
8 iShares Russell 2000 Value ETF 1.65M 0.53% ▲ 1.00% May 29, 2026
9 JNL/T. Rowe Price Capital Appreciation A 1.46M 0.47% ▲ 0.00% Mar 31, 2026
10 Fidelity Select Biotechnology 1.43M 0.46% ▲ 56.66% Apr 30, 2026

Valuation Metrics

Enterprise Value: $5.56B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $5.76B
EBITDA: $-130.68M
Book Value: $1.27
Earnings/Share: $-0.93
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -17.92%
ROE (TTM): -69.86%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 10.04x 0.02x 0.18x N/A -0.04x
2024-12-31 9.84x 0.02x 0.16x N/A -0.06x
2023-12-31 12.26x 0.01x 0.20x N/A -0.03x
2022-12-31 9.13x 0.01x 0.20x -1.23x -0.01x
2021-12-31 15.92x 0.00x 0.09x -2.24x 0.00x
2020-12-31 8.77x -0.01x 1.91x -325.15x -0.02x
2019-12-31 18.59x -0.05x 1.25x N/A -0.06x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ERAS.US!